Single-Cell Analysis Transcriptomics Global Market Report 2025

The single-cell analysis transcriptomics market size has grown rapidly in recent years. It will grow from $0.97 billion in 2024 to $1.09 billion in 2025 at a compound annual growth rate (CAGR) of 12.7%. The growth during the historic period can be attributed to the rising demand for personalized medicine, the increasing prevalence of chronic and rare diseases, the emergence of personalized medicine, the growing demand for high-throughput sequencing, and the expanding applications in cancer research.

The single-cell analysis transcriptomics market size is expected to see rapid growth in the next few years. It will grow to $1.74 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth during the forecast period can be attributed to the growing application of single-cell transcriptomics in immunology and neurology, increasing use in drug discovery and development, expanding adoption of precision medicine, government initiatives supporting genomics research, and advancements in the affordability of sequencing technologies. Key trends in the forecast period include advancements in microfluidics and sequencing platforms, the integration of artificial intelligence in data analysis, the development of multi-omics approaches, innovations in single-cell isolation techniques, and a growing focus on spatial transcriptomics.

The growing adoption of personalized medicine is expected to accelerate the expansion of the single-cell analysis transcriptomics market. Personalized medicine is a tailored approach to medical treatment based on an individual’s genetic profile, lifestyle, and environmental factors. The rise in personalized medicine is driven by advances in genetic sequencing, which enable treatments customized to a patient’s genetic makeup for enhanced effectiveness. Single-cell analysis transcriptomics plays a crucial role by uncovering gene expression profiles at the individual cell level, guiding the development of personalized treatments based on a patient’s unique biology. This approach improves therapeutic outcomes, reduces side effects, and supports early disease diagnosis. For instance, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from the six approvals in 2022. This growing trend in personalized medicine is driving the growth of the single-cell analysis transcriptomics market.

Key companies in the single-cell analysis transcriptomics market are focusing on the development of innovative products, such as single-cell RNA sequencing kits, to streamline workflows and provide deeper insights into cellular heterogeneity. Single-cell RNA sequencing kits are specialized tools designed to isolate and analyze gene expression at the individual cell level, enabling researchers to uncover cellular diversity and gain a better understanding of complex biological processes. For instance, in June 2022, Fluent BioSciences Inc., a US-based biotechnology company specializing in single-cell analysis technologies, launched the PIPseq T2 and T20 v3 kits. These kits capture up to 2,000 and 20,000 single cells or nuclei per reaction, offering sensitive, scalable, and flexible transcriptomic analysis. The kits are suitable for both low-cell diversity studies and large-scale solid tissue profiling, making them a cost-effective and accessible option for advanced RNA sequencing.

In May 2024, Bruker Corporation, a US-based manufacturer of scientific instruments, acquired NanoString Technologies for approximately $392.6 million. This acquisition aims to integrate NanoString’s gene expression profiling and spatial transcriptomics solutions into Bruker’s expanding spatial biology portfolio. The integration of NanoString’s technology will enhance Bruker’s capabilities in discovery and translational research, positioning them as a leader in single-cell and spatial biology innovations.

Major players in the single-cell analysis transcriptomics market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Agilent Technologies Inc., Sartorius Aktiengesellschaft, Illumina Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., 10x Genomics Inc., Abcam Limited, Novogene Co. Ltd., Standard BioTools Inc., Akoya Biosciences Inc., Parse Biosciences Inc., Cell Microsystems Inc., Mission Bio Inc., Relation Therapeutics Ltd., CYTENA GmbH, Fluent BioSciences.

North America was the largest region in the single-cell analysis transcriptomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in single-cell analysis transcriptomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the single-cell analysis transcriptomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Single-cell transcriptomics is a powerful technique that enables the study of gene expression at the individual cell level. It helps identify cellular heterogeneity and unique transcriptional profiles within complex tissues. This approach allows researchers to uncover cellular diversity, discover rare cell types, trace developmental lineages, and gain deeper insights into disease mechanisms.

The main component types of single-cell transcriptomics include equipment, consumables, software, and services. In single-cell transcriptomics, equipment is used for precise RNA analysis at the individual cell level, advancing genomic research and personalized medicine. Various technologies, such as single-cell RNA sequencing, microfluidics-based techniques, and others, are employed for applications including clinical diagnostics, developmental biology, drug discovery, and more. These tools are used by a wide range of end-users, including academic and research institutions, hospitals and diagnostic centers, and pharmaceutical and biotechnology companies.

The single-cell analysis transcriptomics market research report is one of a series of new reports that provides single-cell analysis transcriptomics market statistics, including the single-cell analysis transcriptomics industry global market size, regional shares, competitors with the single-cell analysis transcriptomics market share, detailed single-cell analysis transcriptomics market segments, market trends, opportunities, and any further data you may need to thrive in the single-cell analysis transcriptomics industry. This single-cell analysis transcriptomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The single-cell analysis transcriptomics market consists of revenues earned by entities by providing services such as data analysis and interpretation, sample preparation, and customized gene expression profiling solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The single-cell analysis transcriptomics market includes sales of RNA extraction kits, library preparation kits, cnd DNA synthesis kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.